This article was originally published in The Gray Sheet
Senate bill (1764) sponsored by Sen. Lieberman (D-Conn.) would give net operating loss refunds for biotech companies researching diagnostic devices for biological or chemical agents used in terrorist attacks. S 1764 is expected to merge with the Bioweapons Preparedness Act of 2001 (S 1715), sponsored by Sens. Frist (R-Tenn.) and Kennedy (D-Mass.), which grants the Office of Homeland Security the authority to set research priorities that would help fight bioterrorism. Companies working on named priorities would be eligible for incentives including a zero capital gains tax rate on any gains realized on the stock. The bill would apply to firms with less than $750,000 in paid-in capital...
You may also be interested in...
Sen. Joe Lieberman's (D-Conn.) bill to provide incentives for development of bioterrorism countermeasures is being revised to increase attention on diagnostics
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.